Lamivudine Mylan

Lamivudine Mylan

lamivudine

Manufacturer:

Viatris

Distributor:

Atlanta Medicare
Concise Prescribing Info
Contents
Lamivudine
Indications/Uses
Part of antiretroviral combination therapy for HIV patients.
Dosage/Direction for Use
Adult & adolescent >12 yr 150 mg bid or 300 mg once daily. Childn 3 mth to 12 yr 4 mg/kg bid up to max 300 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Not for monotherapy use. Moderate to severe renal impairment. May cause high rate or urological failure & emergence of resistance at an early stage w/ tenofovir disoproxil fumarate & abacavir or didanosine. Opportunistic infections & other HIV complications. Pancreatitis, lactic acidosis, mitochondrial dysfunction, lipodystrophy, immune reactivation syndrome. Chronic hepatitis B or C, hepatomegaly or other known risk factors for liver disease & hepatic steatosis. Periodic monitoring of liver function test & markers of HBV replication. Childn <3 mth. Pregnancy, lactation.
Adverse Reactions
Headache, insomnia; cough, nasal symptoms; nausea, vomiting, abdominal pain or cramps, diarrhoea; rash, alopecia; arthralgia, muscle disorders; fatigue, malaise, fever.
Drug Interactions
Increase in lamivudine exposure w/ co-trimoxazole. Ganciclovir, foscarnet. Inhibits intracellular phosphorylation of zalcitabine.
MIMS Class
ATC Classification
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Lamivudine Mylan FC tab 150 mg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in